Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Toyama Chemical Commences PII Study for Solithromycin in Japan
January 16, 2015
- Sumitomo Dainippon Files Latuda Patent Infringement Lawsuits in US against 3 Pharmas
January 16, 2015
- Otsuka Completes Acquisition of Avanir for US$3.56 Billion
January 15, 2015
- Lantus Biosimilar Approved: Eli Lilly Japan, NBI
January 15, 2015
- Takeda to Roll Out Colcrys AG in US
January 14, 2015
- Meiji, Roche, Fedora Tie Up for Development, Commercialization of Beta-Lactamase Inhibitor
January 14, 2015
- Ethical Drug Sales Down 7.6% in November: Crecon Report
January 14, 2015
- Daiichi Sankyo Reaches Settlement with US DOJ Following Investigation of Promotional Activities; to Pay US$39 Million
January 14, 2015
- GSK, Nippon Kayaku to End Copromotion of Cancer Drug Tykerb
January 13, 2015
- Otsuka, Fuso to Terminate Cancer Vaccine Deals with OncoTherapy
January 13, 2015
- FDA Approves Edoxaban for AF, VTE: Daiichi Sankyo
January 13, 2015
- GSK Japan Unit to Cut Jobs amid Global Restructuring Move
January 9, 2015
- FDA Accepts sNDA for Aptiom to Treat Partial-Onset Seizures
January 9, 2015
- Takeda Begins PII/III, PIII Studies of Rasagiline
January 9, 2015
- Kyowa Kirin Licenses Anticancer Drug from Syndax in Japan and South Korea
January 9, 2015
- Leading Generic Makers Disclose FY2013 Payments to Healthcare Professionals
January 8, 2015
- Celgene Applies for Additional Indication of Untreated Multiple Myeloma for Revlimid
January 8, 2015
- Hospira’s Oxaliplatin Generics Approved for Unresectable Pancreatic Cancer
January 8, 2015
- Takeda’s Potassium-Competitive Acid Blocker Approved in Japan
January 7, 2015
- Perampanel Meets Primary Endpoint in PIII Study for Asian Patients: Eisai
January 7, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…